CFO Preetam Shah departs; Frank Karbe appointed as new CFO effective Feb 24, 2025

Cidara Therapeutics, Inc.

CFO Preetam Shah to separate on Feb 24, 2025; receives 9 months’ salary, 2024 bonus, and 15 months’ COBRA.
Shah will consult for six months with continued equity vesting during consulting period.
Frank Karbe named CFO effective Feb 24; previously CEO of Better Therapeutics and CFO of Myovant Sciences.
Karbe’s base salary $525K, target bonus 40%, signing bonus $50K; options for 115K shares and RSUs for 57.5K shares.
Severance for Karbe: 9 months’ salary without cause/resignation for good reason; 12 months with change of control.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Frank Karbe

Chief Financial Officer

Cidara Therapeutics, Inc.

Effective: 2025-02-24
Filed: February 18, 2025, 6:59 PM ET

On February 14, 2025, the Board appointed Frank Karbe, 56, as the Company’s Chief Financial Officer (including as its principal financial officer and principal accounting officer), effective as of Mr. Karbe’s employment start date, which is expected to be February 24, 2025

Departed

Preetam Shah

Chief Financial Officer

Cidara Therapeutics, Inc.

Effective: 2025-02-24
Successor: Frank Karbe
Filed: February 18, 2025, 6:59 PM ET

On February 12, 2025, Cidara Therapeutics, Inc. (the “Company”) and Preetam Shah, Ph.D., MBA., the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, mutually agreed to Dr. Shah’s separation from such roles with the Company, effective February 24, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frank Karbe was appointed as Chief Financial Officer at Cidara Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 14, 2025, the Board appointed Frank Karbe, 56, as the Company’s Chief Financial Officer (including as its principal financial officer and principal accounting officer), effective as of Mr. Karbe’s employment start date, which is expected to be February 24, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Preetam Shah resigned as Chief Financial Officer at Cidara Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On February 12, 2025, Cidara Therapeutics, Inc. (the “Company”) and Preetam Shah, Ph.D., MBA., the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, mutually agreed to Dr. Shah’s separation from such roles with the Company, effective February 24, 2025

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-028641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.